Your browser doesn't support javascript.
OUTCOMES OF PEANUT ORAL IMMUNOTHERAPY IN AN ALLERGY CLINIC
Annals of Allergy, Asthma and Immunology ; 127(5):S43, 2021.
Article in English | EMBASE | ID: covidwho-1748293
ABSTRACT

Introduction:

A single tertiary care center has offered oral immunotherapy (OIT) as a clinical service since 2018 using commercial products and subsequently has offered FDA-approved Peanut (Arachis- hypogaea) Allergen Powder-dnfp (PNAP) since July 2020. Shared decision making regarding OIT was based on previous IgE testing, history, and family preference.

Methods:

A retrospective chart review was performed in REDCap database.

Results:

A total of 37 patients initiated OIT (21 commercial products and 16 PNAP). The mean age was 9.25 for commercial product and 7.25 for PNAP with more males than females participating. Co-morbid conditions included allergic rhinitis, asthma, and eczema. Mean peanut IgE prior to starting was 49.75 and Ara h2 was 32.73. Prior reactions to peanut included skin, GI and anaphylaxis. Three children failed an oral challenge prior to starting OIT. There were 5 children that had never ingested peanuts but completed OIT. Minor intermittent side effects including stomach upset and itchy mouth were reported during escalation of both products. Dose adjustment was required for 1 PNAP patient for complaint of dysphagia and pain. There were 4 patients who dropped out of OIT refusal to eat (1), unrelated GI disease (1) and the COVID-19 pandemic (2). All patients upon reaching maintenance are daily dosing with peanuts or chocolate-covered peanut candy. Lifestyle changes reported since reaching maintenance include eating in restaurants previously avoided and ingesting foods with labels stating “may contain peanuts,” and “foods processed in a facility with peanuts.”

Conclusions:

Peanut OIT is safe and well tolerated in our patient population.
Keywords

Full text: Available Collection: Databases of international organizations Database: EMBASE Language: English Journal: Annals of Allergy, Asthma and Immunology Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: Databases of international organizations Database: EMBASE Language: English Journal: Annals of Allergy, Asthma and Immunology Year: 2021 Document Type: Article